Trials / Unknown
UnknownNCT03734913
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of ZSP1602 in Participants With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1602 in participants with basal cell carcinoma, adenocarcinoma of esophagogastric junction, small cell lung cancer, neuroendocrine neoplasm and other advanced solid tumors.
Conditions
- Basal Cell Carcinoma
- Medulloblastoma
- Adenocarcinoma of Esophagogastric Junction
- Small Cell Lung Cancer
- Neuroendocrine Neoplasm
- Glioblastoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZSP1602 | ZSP1602 capsules for oral administration |
Timeline
- Start date
- 2019-01-25
- Primary completion
- 2021-07-31
- Completion
- 2021-07-31
- First posted
- 2018-11-08
- Last updated
- 2020-07-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03734913. Inclusion in this directory is not an endorsement.